Ziprasidone in bipolar disorder

Expert Opinion on Pharmacotherapy

Volumn 7, Issue 9, 2006, Pages 1221-1228

  Versiani, Marcio ^a  

^a FEDERAL UNIVERSITY OF RIO DE JANEIRO   (Brazil)

Author keywords

Bipolar disorder; Clinical trials; Drug therapy; Mania; Olanzapine; Review; Ziprasidone

Indexed keywords

AMITRIPTYLINE; ANTICONVULSIVE AGENT; ARIPIPRAZOLE; BENZODIAZEPINE DERIVATIVE; CARBAMAZEPINE; GLUCOSE; HALOPERIDOL; IMIPRAMINE; LAMOTRIGINE; LIPID; LITHIUM; MOOD STABILIZER; NEUROLEPTIC AGENT; NORADRENALIN TRANSPORTER; OLANZAPINE; PROLACTIN; QUETIAPINE; RISPERIDONE; SEROTONIN 1A RECEPTOR; SEROTONIN 1D RECEPTOR; SEROTONIN 2 RECEPTOR; SEROTONIN 2A RECEPTOR; SEROTONIN 2C RECEPTOR; VALPROIC ACID; ZIPRASIDONE;

AGITATION; AGRANULOCYTOSIS; AKATHISIA; ARTICLE; BIPOLAR DISORDER; BIPOLAR MANIA; CLINICAL TRIAL; COGNITIVE DEFECT; DIABETES MELLITUS; DIZZINESS; DOSE RESPONSE; DRUG BIOAVAILABILITY; DRUG BLOOD LEVEL; DRUG CLEARANCE; DRUG DOSE REGIMEN; DRUG EFFICACY; DRUG ERUPTION; DRUG HALF LIFE; DRUG MECHANISM; DRUG POTENTIATION; DRUG SAFETY; DRUG STRUCTURE; DRUG TOLERABILITY; EXTRAPYRAMIDAL SYMPTOM; EXTRAPYRAMIDAL SYNDROME; FOOD DRUG INTERACTION; GLUCOSE BLOOD LEVEL; HUMAN; HYPOTHYROIDISM; INSOMNIA; KIDNEY FAILURE; LIPID BLOOD LEVEL; LIVER FAILURE; LONG TERM CARE; META ANALYSIS; METABOLIC DISORDER; MOTOR DYSFUNCTION; NAUSEA; OPEN STUDY; ORTHOSTATIC HYPOTENSION; PANCREATITIS; PROLACTIN BLOOD LEVEL; QT PROLONGATION; RECEPTOR AFFINITY; RECEPTOR BLOCKING; SEDATION; SIDE EFFECT; SOMNOLENCE; SYSTEMATIC REVIEW; TARDIVE DYSKINESIA; TREMOR; WEIGHT GAIN;

ANTIMANIC AGENTS; ANTIPSYCHOTIC AGENTS; BIPOLAR DISORDER; DRUG ADMINISTRATION SCHEDULE; DRUG THERAPY, COMBINATION; HUMANS; LITHIUM; PIPERAZINES; PRACTICE GUIDELINES; RANDOMIZED CONTROLLED TRIALS; THIAZOLES;

EID: 33745459809     PISSN: 14656566     EISSN: None     Source Type: Journal    
DOI: 10.1517/14656566.7.9.1221     Document Type: Article

References (52)

1. AMERICAN PSYCHIATRIC ASSOCIATION: Diagnostic and Statistical Manual of Mental Disorders (Fourth Edition). American Psychiatric Association, Washington DC, USA (2000).
2. HIRSCHFELD RM, CALABRESE JR, WEISSMAN MM et al: Screening for bipolar disorder in the community. J. Clin. Psychiatry (2003) 64(1):53-59.
3. JUDD LL, AKISKAL HS: The prevalence and disability of bipolar spectrum disorders in the US population: re-analysis of the ECA database taking into account subthreshold cases. J. Affect. Disord. (2003) 73(1-2):123-131.
4. PINI S, DE QUEIROZ V, PAGNIN D et al.: Prevalence and burden of bipolar disorders in European countries. Eur. Neuropsychopharmacol. (2005) 15(4):425-434.
5. DAS AK, OLFSON M, BLANCO C et al.: Screening for bipolar disorder in a primary care practice. JAMA (2005) 293(8):956-963.
6. JUDD LL, AKISKAL HS, SCHETTLER PJ et al.: A prospective investigation of the natural history of the long-term weekly symptomatic status of bipolar II disorder. Arch. Gen. Psychiatry (2003) 60(3):261-269.
7. JUDD LL, AKISKAL HS, SCHETTLER PJ et al.: The long-term natural history of the weekly symptomatic status of bipolar I disorder. Arch. Gen. Psychiatry (2002) 59(6):530-537.
8. POST RM, DENICOFF KD, LEVERICH GS et al.: Morbidity in 258 bipolar outpatients followed for 1 year with daily prospective ratings on the NIMH life chart method. J. Clin. Psychiatry (2003) 64(6):680-690.
9. JUDD LL, AKISKAL HS, SCHETTLER PJ et al.: Psychosocial disability in the course of bipolar I and II disorders: a prospective, comparative, longitudinal study. Arch. Gen. Psychiatry (2005) 62(12):1322-1330.
10. The global burden of disease and injury series. In: A Comprehensive Assessment of Mortality and Disability from Diseases, Injuries and Risk Factors in 1990 and Projected to 2020, Mass (Volume 1). CL Murra, AD Lopez (Eds), Harvard School of Public Health on behalf of the World Health Organization and the World Bank; Harvard University Press, Cambridge, MA, USA (1996).
11. SAJATOVIC M: Bipolar disorder: disease burden. Am. J. Manag. Care (2005) 11:S80-S84.
12. MACQUEEN GM, YOUNG LT, JOFFE RT: A review of psychosocial outcome in patients with bipolar disorder. Acta Pychiatr. Scand. (2001) 103:163-170.
13. GOLDBERG JF, HARROW M: Consistency of remission and outcome in bipolar and unipolar mood disorders: a 10-year prospective follow-up. J. Affect. Disord. (2004) 81(2):123-131.
14. CHEN YW, DILSAVER SC: Lifetime rates of suicide attempts among subjects with bipolar and unipolar disorders relative to subjects with other axis I disorders. Biol. Psychiatry (1996) 39(10):869-896.
15. KESSLER RC, BORGES G, WALTERS EE: Prevalence of and risk factors for lifetime suicide attempts in the National Comorbidity Survey. Arch. Gen. Psychiatry (1999) 56(7):617-626.
16. HOYER EH, OLESEN AV, MORTENSEN PB: Suicide risk in patients hospitalised because of an affective disorder: a follow-up study, 1973-1993. J. Affect. Disord. (2004) 78:209-217.
17. JAMISON KR: Suicide and bipolar disorder. J Clin. Pychiatry (2000) 61 (Suppl. 9):47-51.
18. AMERICAN PSYCHIATRIC ASSOCIATION: Work group on bipolar disorder. Practice guidelines for the treatment of patients with bipolar disorder revised. Am. J. Psychiatry (2002) 159(Suppl.):1-50.
19. SUPPES T, DENNEHY EB, HIRSCHFELD RM et al.: The Texas implementation of medication algorithms: update to the algorithms for treatment of bipolar I disorder. J. Clin. Psychiatry (2005) 66(7):870-886.
20. BLANCO C, LAJE G, OLFSON M et al.: Trends in the treatment of bipolar disorder by outpatient psychiatrists. Am. J. Psychiatry (2002) 159(6):1005-1010.
21. SERNYAK MJ, GRIFFIN RA, JOHNSON RM et al. Neuroleptic exposure following inpatient treatment of acute mania with lithium and neuroleptic. Am. J. Psychiatry (1994) 151(1):133-135.
22. TOHEN M, ZHANG F, TAYLOR CC et al.: A meta-analysis of the use of typical antipsychotic agents in bipolar disorder. J. Affect. Disord. (2001) 65(1):85-93.
23. APIQUIAN R, FRESAN A, DE LA FUENTE-SANDOVAL C et al.: Survey on psychosis treatment in Mexico: perception and antipsychotic prescription patterns. BMC. Psychiatry (2004) 4:12.
24. BERK M, DODD S: Efficacy of atypical antipsychotics in bipolar disorder. Drugs (2005) 65(2):257-269.
25. NEMEROFF CB, MASAND PS, LIEBERMAN JA et al.: From clinical research to clinical practice: a 4-year review of ziprasidone. CNS Spectr. (2005) 10(11):1S-20S.
26. GROF P: Selecting effective long-term treatment for bipolar patients: monotherapy and combinations. J. Clin. Psychiatry (2003) 64(Suppl. 5):53-61.
27. BOWDEN CL: Atypical antipsychotic augmentation of mood stabilizer therapy in bipolar disorder. J. Clin. Psychiatry (2005) 66(Suppl. 3):12-19.
28. SCOTT J, POPE M: Nonadherence with mood stabilizers: prevalence and predictors. J. Clin. Psychiatry (2002) 63(5):384-390.
29. SEEGER TF, SEYMOUR PA, SCHMIDT AW et al.: Ziprasidone (CP-88,059): a new antipsychotic with combined dopamine and serotonin receptor antagonist activity. J. Pharmacol. Exp. Ther. (1995) 275(1):101-113.
30. SCHMIDT AW, LEBEL LA, HOWARD HR Jr et al.: Ziprasidone: a novel antipsychotic agent with a unique human receptor binding profile. Eur. J. Pharmacol. (2001) 425(3):197-201.
31. STAHL SM, SHAYEGAN DK: The psychopharmacology of ziprasidone: receptor-binding properties and real-world psychiatric practice. J. Clin. Psychiatry (2003) 64(Suppl. 19):6-12.
32. PRAKASH C, KAMEL A, GUMMERUS J et al.: Metabolism and excretion of a new antipsychotic drug, ziprasidone, in humans. Drug Metab. Dispos. (1997) 25(7):863-872.
33. PRAKASH C, KAMEL A, CUI D et al.: Identification of the major human liver cytochrome P450 isoform(s) responsible for the formation of the primary metabolites of ziprasidone and prediction of possible drug interactions. Br. J. Clin. Pharmacol. (2000) 49(Suppl. 1):35S-42S.
34. MIAO Z, KAMEL A, PRAKASH C: Characterization of a novel metabolite intermediate of ziprasidone in hepatic cytosolic factions of rat, dog, and human by ESI-MS/MS, hydrogen/deuterium exchange, and chemical derivatization. Drug Metab. Dipos. (2005) 33(7):879-883.
35. MICELI JJ, ANZIANO RJ, ROBARGE L et al.: The effect of carbamazepine on the steady-state pharmacokinetics of ziprasidone in healthy volunteers. Br. J. Clin. Pharmacol. (2000) 49(Suppl. 1):65S-70S.
36. APSELOFF G, MULLET D, WILNER KD et al.: The effects of ziprasidone on steady-state lithium levels and renal clearance of lithium. Br. J. Clin. Pharmacol. (2000) 49(Suppl. 1):61S-64S.
37. WILNER KD, TENSFELDT TG, BARIS B et al.: Single- and multiple-dose pharmacokinetics of ziprasidone in healthy young and elderly volunteers. Br. J. Clin. Pharmacol. (2000) 49(Suppl. 1):15S-20S.
38. HAMELIN BA, ALLARD S, LAPLANTE L et al.: The effect of timing of a standard meal on the pharmacokinetics and pharmacodynamics of the novel atypical antipsychotic agent ziprasidone. Pharmacotherapy (1998) 18(1):9-15.
39. KECK PE JR, VERSIANI M, POTKIN S et al.: Ziprasidone in the treatment of acute bipolar mania: a three-week, placebo-controlled, double-blind, randomized trial. Am. J. Psychiatry (2003) 160(4):741-748.
40. POTKIN SG, KECK PE JR, SEGAL S et al.: Ziprasidone in acute bipolar mania: a 21-day randomized, double-blind, placebo-controlled replication trial. J. Clin. Psychopharmacol. (2005) 25(4):301-310.
41. DUNN J, RAMEY T, GILLER E et al.: Efficacy and tolerability of ziprasidone in acute bipolar mania: 12 week double blind study. Eur. Psychiatry (2005) 20:(Suppl. 1):S128-P0305.
42. POTKIN SG, KECK PE, GILLER E et al.: Ziprasidone in bipolar mania: efficacy across patient subgroups. Biol. Psychiatry (2004) 55:8(Suppl. 1):85S.
43. ZAJECKA J, MURRAY S, RAMEY T et al.: Efficacy of ziprasidone in dysphoric mania: analysis of 3 double-blind studies. Biol. Pychiatry (2005) 57(Suppl. 8):171S.
44. ENDICOTT J, COHEN J, NEE J, FLEISS J et al.: Hamilton depression rating scale. Extracted from regular and change versions of the schedule for affective disorders and schizophrenia. Arch. Gen. Psychiatry (1981) 38(1):98-103.
45. VERSIANI M, KECK P, POTKIN G et al.: Efficacy and safety of ziprasidone in bipolar disorder: long-term data. Eur. Pychiatry (2005) 20(Suppl. 1):S128.
46. WARRINGTON L, POTKIN SG, ICE K et al.: Ziprasidone's long-term efficacy in subpopulations with bipolar mania. Biol. Psychiatry (2005) 57(Suppl. 1):109S.
47. WEISLER R, WARRINGTON L, DUNN J: Adjunctive ziprasidone in bipolar mania: short- and long-term data. Biol. Psychiatry (2004) 55(Suppl. 1):43S.
48. WARRINGTON L, DUNN J, MANDEL F: Ziprasidone safety and tolerability in bipolar mania: review of trial data. 158th American Psychiatric Association meeting, Atlanta, GA, USA (2005). Poster.
49. DANIEL DG: Tolerability of ziprasidone: an expanding perspective. J. Clin. Psychiatry (2003) 64(Suppl. 19):40-49.
50. GLASSMAN AH: Schizophrenia, antipsychotic drugs, and cardiovascular disease. J. Clin. Psychiatry (2005) 66(Suppl. 6):5-10.
51. DUNNER DL: Safety and tolerability of emerging pharmacological treatments for bipolar disorder. Bipolar Disord. (2005) 7(4):307-325.
52. AMERICAN DIABETES ASSOCIATION, AMERICAN PSYCHIATRIC ASSOCIATION, AMERICAN ASSOCIATION OF CLINICAL ENDOCRINOLOGISTS, NORTH AMERICAN ASSOCIATION FOR THE STUDY OF OBESITY: Consensus development conference in antipsychotic drugs and obesity and diabetes. Diabetes Care (2004) 27:596-601.